Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting
-
Tech drags down world stocks, oil dips on supply hopes
-
Scorching heat shuts Paris landmarks early as France swelters
-
Shootout traps tourists at Rio sunrise lookout
-
Ipswich hire Gary O'Neil as manager
-
Heatwave sparks health warnings across Europe
-
Lake wins Wales captaincy race ahead of Morgan
-
Starmer vows 'orderly' transition as Labour MPs mull bid to be PM
-
Reports of Dupont inclusion in France squad 'bordering on annoying' says Galthie
-
ACTIVIST SHAREHOLDER FILES SCHEDULE 13D IN EQUUS TOTAL RETURN, INC.
-
England coach McCullum denies rift with 'good friend' Stokes
-
Europe: the world's fastest-warming continent
-
Taliban officials hold EU migration talks in Brussels
-
Gennaro Gattuso returns to coaching with Lazio after Italy debacle
-
Kenya halts US Ebola facility: health minister tells court
-
Why the heat is wreaking havoc on Europe's trains
-
Zelensky to skip key Ukraine conference in Poland over WWII row
-
Seoul leads rout for tech shares as oil prices dip
-
Europe heatwave closes schools, threatens health
-
India monsoon sweeps north but brings less rain than usual
-
Germany eyes longer working lives in pension reform plan
-
UK and markets await Burnham's economic plans
-
Heineken names new CEO after predecessor's shock departure
-
Banned Vondrousova insists she has 'never doped'
-
Schools plan to close as UK braces for record-breaking heatwave
-
UN chief urges AI firms to 'come clean' over environmental footprint
-
More records set to fall as deadly Europe heatwave drags on
-
Israel's 'deliberate targeting' of children part of ongoing Gaza 'genocide': UN probe
-
England, Ghana eye last 32 as Portugal look for lift-off
-
Sri Lanka troops to battle deadly dengue mosquitoes as cases rise
-
Iran says to oversee Hormuz as Swiss talks conclude
-
Diaspora World Cup champions diversity over division
-
Guns, drones and doves: War reshapes Ukrainian jewellery scene
-
Australia withholds Pacific climate fund reports over risk of diplomatic 'damage'
-
Kenya police violence victims say compensation promise a 'smokescreen'
-
Indian startup head appointed as new WhatsApp boss
-
EU bets on digital euro to cut US tech addiction
-
Antetokounmpo joining Miami Heat in blockbuster: reports
-
Fineanganofo rethinks Newcastle move after All Blacks call-up
-
'Let's be realistic': Haaland cools Norway's World Cup expectations
-
Stocks fluctuate after Wall St sell-off, crude holds losses on peace talks
-
Lightning, downpour, a two-hour delay: bad weather hits the World Cup
-
Ultra-reclusive Turkmenistan slowly opens up to tourists
-
Two-goal Haaland fires Norway into World Cup last 32
-
Marc Bloch, historian and Resistance hero, joins France's Pantheon greats
-
Last one the best one? How Messi keeps doing it at World Cup
-
Ronaldo 'a role model' says Portugal coach after slow World Cup start
-
North Korea's Kim vows to accelerate military buildup
-
Savea 'embraces challlenge' of leading All Blacks towards World Cup
-
Latin America's resurgent right notches another win in Colombia
-
Mbappe scores twice as France beat Iraq at World Cup after two-hour storm delay
Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting
Moderna to host an investor event via webcast on Monday, June 1 at 6:15 PM CDT
CAMBRIDGE, MA / ACCESS Newswire / April 21, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its investigational mRNA therapeutics have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 29 - June 2 in Chicago, IL.
The presentation details are as follows:
Oral Presentation:
Abstract #9500: Individualized neoantigen therapy intismeran autogene (intismeran) plus pembrolizumab (pembro) in resected melanoma: 5-year update of the KEYNOTE-942 study
Session Type/Title: Oral Abstract Session - Melanoma/Skin Cancers
Data & Time: June 1, 8:00 AM - 11:00 AM CT
Presenter: Matteo S. Carlino, MBBS, PhD, FRACP
Poster Presentations:
Abstract #9564: Intismeran autogene to induce de novo neoantigen-specific T cells as adjuvant therapy in melanoma
Session Type/Title: Poster Session - Melanoma/Skin Cancers: Poster Board #280
Date & Time: May 31, 9:00 AM - 12:00 PM CDT
Presenter: Ryan J. Sullivan, MD
Abstract #TPS7580: A phase 1/2 study of mRNA-2808 in participants with relapsed or refractory multiple myeloma
Session Type/Title: Poster Session - Hematologic Malignancies - Plasma Cell Dyscrasia: Poster Board #457b
Date & Time: June 1, 9:00 AM - 12:00 PM CDT
Presenter: Hans C. Lee, MD
Intismeran autogene is jointly developed by Moderna and Merck, known as MSD outside of the United States and Canada.
Moderna Investor Event
Moderna will host a live webcast on Monday, June 1, from 6:15 - 7:15 PM CDT. The webcast will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna's website for at least 30 days following the presentation.
About Moderna
Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more.
With a global team and a unique culture, driven by the company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X, Facebook, Instagram, YouTube and LinkedIn.
Moderna Contacts
Media:
Chris Ridley
Vice President, Global Head of Communications
+1 617-800-3651
[email protected]
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
[email protected]
SOURCE: Moderna, Inc.
View the original press release on ACCESS Newswire
J.Oliveira--AMWN
